Publication: Vismodegib in PAMAM-dendrimers for potential theragnosis in skin cancer
Date
2022
Authors
Ybarra, David Emanuel
Ramirez, Luis Felipe Barraza
Aguayo Frias, Eliana Taís
Lillo, Rolando Cristian Rodrigo
Alonso Del Valle, Silvia
Martinetti Montanari, Jorge Aníbal
Alvira, Fernando Carlos
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Abstract
Vismodegib (VDG) is an antineoplastic, a first-in-class Hedgehog signaling pathway inhibitor, indicated to treat locally advanced or metastatic basal cell carcinoma. Treatment with this drug was approved in 2012 by the US-FDA for oral administration (dose of 150 mg per day) in patients with a refusal of radiotherapy or surgery. However, it presents side effects that influence patient adherence to treatment. Polyamidoamine (PAMAM) dendrimers (D) are promising drug-delivery systems with high water solubility. Additionally, they can penetrate the skin barrier. In this work, we used amine-terminated (DG4.0) and carboxy-terminated (DG4.5) dendrimers of generation 4.0 and 4.5, respectively. We demonstrated that the complexation of VDG with dendrimers (D:VDG complexes) increased its concentration in the aqueous medium. We carried out characterization studies of the complexes to understand how dendrimers interact with VDG, and we found the optimal molar ratios of complexation.
Description
Keywords
Citation
Ybarra, David Emanuel; Calienni, Maria Natalia; Ramirez, Luis Felipe Barraza; Aguayo Frias, Eliana Taís; Lillo, Rolando Cristian Rodrigo; et al. (2022) Vismodegib in PAMAM-dendrimers for potential theragnosis in skin cancer. 7; 100053-100066
Collections
Version History
You are currently viewing version 1 of the item.